A groundbreaking discovery could be a game-changer in the battle against cancer as Harvard-led researchers have zeroed in on a statin drug that appears to block a pathway which may lead to cancer from chronic inflammation, a recent study from the Mass General Cancer Center, a Harvard affiliate, reveals.
Their study, published in The Harvard Gazette, highlighted that the cholesterol-lowering drug pitavastatin suppresses inflammation in the skin and pancreas that can escalate to cancer when chronic. This new avenue of research has tossed conventional wisdom on its head by potentially offering a novel use for drugs previously pigeonholed into combating high cholesterol. Senior author Shawn Demehri, an authority at the Center for Cancer Immunology and the Cutaneous Biology Research Center of Massachusetts General Hospital, underscored the importance of their work, saying "Chronic inflammation is a major cause of cancer worldwide."
Demehri, also an associate professor of dermatology at Harvard Medical School and the Bob and Rita Davis Family MGH Research Scholar for 2023-2028, expanded on the mechanisms at play: "We investigated the mechanism by which environmental toxins drive the initiation of cancer-prone chronic inflammation in the skin and pancreas," according to The Harvard Gazette. The labs delved into a spectrum of research including cell lines, animal models, and human tissue, indicating that environmental aggravants like allergens and chemical irritants activate signaling pathways that lead to IL-33 protein production, stoking inflammation that, in excess, can be a precursor to cancerous developments.
In mouse-based tests, pitavastatin was shown to stifle this harmful inflammation, consequently preventing such inflammation-related cancers from taking hold. The study's findings are raising hopes of a preventative treatment for one of the deadliest diseases known to mankind, which mocks previous means of addressing the chronic conditions leading up to cancer. Further supporting their findings, human pancreatic tissue samples from patients displayed overflowed IL-33 in cases of chronic pancreatitis and pancreatic cancer compared with normal tissue samples, a hint at overriding significance. Additionally, healthcare records spanning North America and Europe, involving over 200 million people, demonstrated a promising trend: pitavastatin users faced a considerably lower risk of developing chronic pancreatitis and pancreatic cancer.
"Next, we aim to further examine the impact of statins in preventing cancer development in chronic inflammation in liver and gastrointestinal tract and to identify other novel, therapeutic approaches to suppress cancer-prone chronic inflammation," Demehri told The Harvard Gazette. This research was fueled by contributions from the Burroughs Wellcome Fund, the LEO Foundation, the Sidney Kimmel Foundation, and the National Institutes of Health, which may pave the way for revolutionary tactics in cancer prevention and open new chapters in the understanding of the drugs we thought we knew.
